Literature DB >> 26235382

Immunogenetics of autoimmune thyroid diseases: A comprehensive review.

Hanna J Lee1, Cheuk Wun Li1, Sara Salehi Hammerstad2, Mihaela Stefan1, Yaron Tomer3.   

Abstract

Both environmental and genetic triggers factor into the etiology of autoimmune thyroid disease (AITD), including Graves' disease (GD) and Hashimoto's thyroiditis (HT). Although the exact pathogenesis and causative interaction between environment and genes are unknown, GD and HT share similar immune-mediated mechanisms of disease. They both are characterized by the production of thyroid autoantibodies and by thyroidal lymphocytic infiltration, despite being clinically distinct entities with thyrotoxicosis in GD and hypothyroidism in HT. Family and population studies confirm the strong genetic influence and inheritability in the development of AITD. AITD susceptibility genes can be categorized as either thyroid specific (Tg, TSHR) or immune-modulating (FOXP3, CD25, CD40, CTLA-4, HLA), with HLA-DR3 carrying the highest risk. Of the AITD susceptibility genes, FOXP3 and CD25 play critical roles in the establishment of peripheral tolerance while CD40, CTLA-4, and the HLA genes are pivotal for T lymphocyte activation and antigen presentation. Polymorphisms in these immune-modulating genes, in particular, significantly contribute to the predisposition for GD, HT and, unsurprisingly, other autoimmune diseases. Emerging evidence suggests that single nucleotide polymorphisms (SNPs) in the immunoregulatory genes may functionally hinder the proper development of central and peripheral tolerance and alter T cell interactions with antigen presenting cells (APCs) in the immunological synapse. Thus, susceptibility genes for AITD contribute directly to the key mechanism underlying the development of organ-specific autoimmunity, namely the breakdown in self-tolerance. Here we review the major immune-modulating genes that are associated with AITD and their potential functional effects on thyroidal immune dysregulation. Published by Elsevier Ltd.

Entities:  

Keywords:  Autoimmune thyroid disease; Autoimmunity; Graves' disease; Hashimoto's thyroiditis; Immunogenetics; Polymorphism

Mesh:

Year:  2015        PMID: 26235382      PMCID: PMC4628844          DOI: 10.1016/j.jaut.2015.07.009

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  130 in total

1.  Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1.

Authors:  Masahiro Ono; Hiroko Yaguchi; Naganari Ohkura; Issay Kitabayashi; Yuko Nagamura; Takashi Nomura; Yoshiki Miyachi; Toshihiko Tsukada; Shimon Sakaguchi
Journal:  Nature       Date:  2007-03-21       Impact factor: 49.962

2.  Association of the BTNL2 rs2076530 single nucleotide polymorphism with Graves' disease appears to be secondary to DRB1 exon 2 position beta74.

Authors:  M J Simmonds; J M Heward; J C Barrett; J A Franklyn; S C L Gough
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

3.  A C/T polymorphism in the 5' untranslated region of the CD40 gene is associated with later onset of Graves' disease in Japanese.

Authors:  Tokunori Mukai; Yuji Hiromatsu; Tomoka Fukutani; Michiko Ichimura; Hiroo Kaku; Ikuyo Miyake; Kentaro Yamada
Journal:  Endocr J       Date:  2005-08       Impact factor: 2.349

Review 4.  Autoimmune thyroid disorders.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Alda Corrado; Andrea Di Domenicantonio; Poupak Fallahi
Journal:  Autoimmun Rev       Date:  2014-10-25       Impact factor: 9.754

5.  Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells.

Authors:  Ye Zheng; Steven Z Josefowicz; Arnold Kas; Tin-Tin Chu; Marc A Gavin; Alexander Y Rudensky
Journal:  Nature       Date:  2007-01-21       Impact factor: 49.962

6.  Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families.

Authors:  Yaron Tomer; Yoshiyuki Ban; Erlinda Concepcion; Giuseppe Barbesino; Ronald Villanueva; David A Greenberg; Terry F Davies
Journal:  Am J Hum Genet       Date:  2003-09-12       Impact factor: 11.025

7.  Dissecting the role of the FOXP3 gene in the joint genetic susceptibility to autoimmune thyroiditis and diabetes: a genetic and functional analysis.

Authors:  Cheuk Wun Li; Erlinda Concepcion; Yaron Tomer
Journal:  Gene       Date:  2014-12-03       Impact factor: 3.688

8.  'Linkage analysis of thyroid antibody production: evidence for shared susceptibility to clinical autoimmune thyroid disease.

Authors:  Yoshiyuki Ban; David A Greenberg; Terry F Davies; Eric Jacobson; Erlinda Concepcion; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2008-06-17       Impact factor: 5.958

9.  Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B-cell tolerance.

Authors:  Laurence Menard; Tineke Cantaert; Nicolas Chamberlain; Stuart G Tangye; Sean Riminton; Joseph A Church; Amy Klion; Charlotte Cunningham-Rundles; Kim E Nichols; Eric Meffre
Journal:  J Allergy Clin Immunol       Date:  2013-12-25       Impact factor: 10.793

10.  The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs.

Authors:  Sarah E Allan; Laura Passerini; Rosa Bacchetta; Natasha Crellin; Minyue Dai; Paul C Orban; Steven F Ziegler; Maria Grazia Roncarolo; Megan K Levings
Journal:  J Clin Invest       Date:  2005-10-06       Impact factor: 14.808

View more
  76 in total

Review 1.  Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers.

Authors:  Christoph Langenstein; Diana Schork; Klaus Badenhoop; Eva Herrmann
Journal:  Rev Endocr Metab Disord       Date:  2016-12       Impact factor: 6.514

2.  Interferon-α Triggers Autoimmune Thyroid Diseases via Lysosomal-Dependent Degradation of Thyroglobulin.

Authors:  Larissa C Faustino; Angela Lombardi; Julio Madrigal-Matute; Randall P Owen; Steven K Libutti; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

Review 3.  The thyroid, the eyes and the gut: a possible connection.

Authors:  D Covelli; M Ludgate
Journal:  J Endocrinol Invest       Date:  2017-01-07       Impact factor: 4.256

4.  A Mouse Thyrotropin Receptor A-Subunit Transgene Expressed in Thyroiditis-Prone Mice May Provide Insight into Why Graves' Disease Only Occurs in Humans.

Authors:  Sandra M McLachlan; Holly A Aliesky; Basil Rapoport
Journal:  Thyroid       Date:  2019-07-03       Impact factor: 6.568

Review 5.  Pediatric Hypothyroidism: Diagnosis and Treatment.

Authors:  Ari J Wassner
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

6.  Association and gene-gene interaction analyses for polymorphic variants in CTLA-4 and FOXP3 genes: role in susceptibility to autoimmune thyroid disease.

Authors:  Nusrath Fathima; Parimala Narne; Mohammed Ishaq
Journal:  Endocrine       Date:  2019-02-15       Impact factor: 3.633

Review 7.  The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.

Authors:  Angela Ceribelli; Maria De Santis; Natasa Isailovic; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

8.  Association of CD40 Gene Polymorphisms with Susceptibility to Neuromyelitis Optica Spectrum Disorders.

Authors:  Ziyan Shi; Qin Zhang; Hongxi Chen; Xiaohui Miao; Ju Liu; Zhiyun Lian; Huiru Feng; Hongyu Zhou
Journal:  Mol Neurobiol       Date:  2016-08-30       Impact factor: 5.590

9.  Certain HLA alleles are associated with stress-triggered Graves' disease and influence its course.

Authors:  Roberto Vita; Daniela Lapa; Francesco Trimarchi; Giuseppe Vita; Poupak Fallahi; Alessandro Antonelli; Salvatore Benvenga
Journal:  Endocrine       Date:  2016-03-07       Impact factor: 3.633

Review 10.  A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves' disease.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocrine       Date:  2019-09-27       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.